Parkinson’s gene therapy development to restart in summer 2019
Development of the Parkinson’s disease gene therapy that UniQure was previously involved in...
Focus:
-
![Schizophrenia treatment]()
Minerva to explore therapy in treatment-naïve schizophrenia and more
-
![Novo Nordisk oral GLP-1]()
NDAs submitted to the FDA for the first oral GLP-1 receptor agonist
-
![Cell and gene therapy manufacturing 2019]()
Governments are playing a bigger role in cell and gene therapy manufacturing
-
![HIV Juluca]()
ViiV announces long-term positive results for Juluca combination
-
![universal influenza vaccine]()
NIH initiates first clinical trial of universal influenza vaccine
-
![haemophilia A gene therapy]()
Sangamo announces promising early results for haemophilia A gene therapy
Most Read
- ViiV announces long-term positive results for Juluca combination
- NIH initiates first clinical trial of universal influenza vaccine
- Sangamo announces promising early results for haemophilia A gene therapy
- FDA grants AstraZeneca-Merck’s selumetinib breakthrough therapy designation
- Penn presents positive results for targeted leukaemia drug
Company A-Z
Latest Content
Parkinson’s gene therapy development to restart in summer 2019
Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be restarted in a Phase II trial this summer with the help of a private-public entity.
Minerva to explore therapy in treatment-naïve schizophrenia and more
Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients and additional indications with apathy symptoms.
NDAs submitted to the FDA for the first oral GLP-1 receptor agonist
Novo Nordisk has submitted NDAs for what could be the first ever oral GLP-1 based treatment for type II diabetes. What could this mean for the GLP-1 market?
NIH strategy shows promise in hunt for universal influenza vaccine
On April 3, the US National Institutes of Health (NIH) announced the start of a Phase I clinical trial investigating the safety, tolerability, and immunogenicity of its universal influenza vaccine candidate, H1ssF_3928.
Excellent phase 3 trial data for rheumatoid arthritis drug filgotinib – but long road ahead
On 28 March 2019, Gilead and Galapagos announced that their selective JAK1 inhibitor, filgotinib, had met all primary endpoints in its two remaining Phase III rheumatoid arthritis (RA) trials, FINCH 1 and FINCH 3.
Risk of stroke is high even with moderate intake of alcohol
The findings suggest that even drinking one or two glasses of alcohol daily will increase stroke risk by 15%. The study also found no evidence of a protective effect on the heart from light alcohol intake.
Governments are playing a bigger role in cell and gene therapy manufacturing
Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
Increased diagnosis and comprehensive treatment of mood disorders in cases of BED is crucial to recovery
BED is more prevalent than anorexia nervosa and bulimia nervosa. BED is frequently associated with mood disorders, role impairment and reduced quality of life.
Dupixent likely to maintain its position in the market for atopic dermatitis
Atopic dermatitis, also known as eczema, is a chronic condition that makes skin red and itchy. It tends to periodically flare.
Positive findings from Amarin’s REDUCE-IT trial bode well for important Vascepa label expansion
Amarin is seeking an expanded indication for fish oil drug Vascepa to include the reduction in cardiovascular risk.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Go Top
